Literature DB >> 17518359

Effects of solution conditions and surface chemistry on the adsorption of three recombinant botulinum neurotoxin antigens to aluminum salt adjuvants.

Christina Vessely1, Tia Estey, Theodore W Randolph, Ian Henderson, Rajiv Nayar, John F Carpenter.   

Abstract

Botulinum neurotoxin (BoNT) is a biological warfare threat. Protein antigens have been developed against the seven major BoNT serotypes for the development of a recombinant protein vaccine. This study is an evaluation of adsorption profiles for three of the recombinant protein antigens to aluminum salt adjuvants in the development of a trivalent vaccine against BoNT. Adsorption profiles were obtained over a range of protein concentrations. The results document that charge-charge interactions dominate the adsorption of antigen to adjuvant. Optimal conditions for adsorption were determined. However, potency studies and solution stability studies indicated the necessity of using aluminum hydroxide adjuvant at low pH. To improve the adsorption profiles to AlOH adjuvant, phosphate ions were introduced into the adsorption buffers. The resulting change in the adjuvant chemistry led to an improvement of adsorption of the BoNT antigens to aluminum hydroxide adjuvant while maintaining potency. Competitive adsorption profiles were also determined, and showed changes in maximum adsorption from mixed solutions compared to adsorption from individual protein solutions. The adsorption profiles for each protein varied due to differences in adsorption mechanism and affinity for the adjuvant surface. These results emphasize the importance of evaluating competitive adsorption in the development of multivalent vaccine products. (c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17518359     DOI: 10.1002/jps.20880

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry.

Authors:  Tia Estey; Christina Vessely; Theodore W Randolph; Ian Henderson; Latoya Jones Braun; Rajiv Nayar; John F Carpenter
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

2.  Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution.

Authors:  Christina Vessely; Tia Estey; Theodore W Randolph; Ian Henderson; Julianne Cooper; Rajiv Nayar; Latoya Jones Braun; John F Carpenter
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

3.  Patterns of binding of aluminum-containing adjuvants to Haemophilus influenzae type b and meningococcal group C conjugate vaccines and components.

Authors:  Robert B D Otto; Karena Burkin; Saba Erum Amir; Dennis T Crane; Barbara Bolgiano
Journal:  Biologicals       Date:  2015-07-17       Impact factor: 1.856

4.  Development and evaluation of a tetravalent botulinum vaccine.

Authors:  Dan-Yang Shi; Fu-Jia Liu; Zhi-Ying Li; Yun-Yun Mao; Jian-Sheng Lu; Rong Wang; Xiao-Bin Pang; Yun-Zhou Yu; Zhi-Xin Yang
Journal:  Hum Vaccin Immunother       Date:  2022-04-18       Impact factor: 4.526

5.  Mechanism of immunopotentiation and safety of aluminum adjuvants.

Authors:  Harm Hogenesch
Journal:  Front Immunol       Date:  2013-01-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.